Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics tags : Cancer save search
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Published: 2024-04-18 (Crawled : 13:00) - globenewswire.com
ONCT | $8.545 -2.51% -0.11% 65
|
Health Technology
| Email alert
Add to watchlist
onct-534 first cancer treatment for study
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
Published: 2024-04-11 (Crawled : 13:00) - globenewswire.com
CADL | $5.88 -2.81% 30K
|
|
| O: 25.49%
H: 23.75%
C: 13.75%
can-2409 fda drug cancer pancreatic treatment designation for therapeutics
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
Published: 2024-04-10 (Crawled : 13:00) - biospace.com/
CGEN | $1.91 72K
|
Health Technology
|
| O: -2.97%
H: 0.0%
C: 0.0%
com503 cancer research immunology potential
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
MNPR | $0.657 1.08% -3.17% 31
|
Health Technology
|
| O: 4.98%
H: 4.84%
C: 3.23%
mnpr-101 cancer for trial advanced
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
QLGN | $0.3089 -1.94% -6.42% 330
|
Health Technology
|
| O: -2.03%
H: 2.35%
C: -2.76%
association direct cancer research meeting
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
BCTX | $2.19 -3.1% -5.94% 0
|
Professional, Scientific, and T...
|
| O: -3.83%
H: 0.0%
C: 0.0%
breast cancer preclinical for
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
MDNAF | $1.39 21.93% -17.54% 0
|
n/a
|
| O: 18.35%
H: 13.64%
C: 12.4%
mdna11 association cancer ongoing expansion research for meeting results study
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-09 (Crawled : 21:00) - globenewswire.com
MDNAF | $1.39 21.93% -17.54% 0
|
n/a
|
| O: 18.35%
H: 13.64%
C: 12.4%
mdna11 association cancer ongoing expansion research for meeting results study
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
CMPX | $1.42 -4.05% 240K
|
Professional, Scientific, and T...
|
| O: 2.06%
H: 0.0%
C: 0.0%
association tumors cancer research for meeting therapeutics negative
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
RAPT | $7.9 -1.25% -1.2% 0
|
Health Technology
|
| O: 0.0%
H: 3.37%
C: 1.44%
cancer immunotherapy trial therapeutics results
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
MDNAF | $1.39 21.93% -17.54% 0
|
n/a
|
| O: -3.82%
H: 0.0%
C: -13.49%
mdna113 association cancer research preclinical for meeting
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
QLGN | $0.3089 -1.94% -6.42% 330
|
Health Technology
|
| O: 3.2%
H: 0.0%
C: -0.28%
qn-302 association positive cancer research meeting therapeutics
BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
BCTX | $2.19 -3.1% -5.94% 0
|
Professional, Scientific, and T...
|
| O: 1.77%
H: 0.0%
C: 0.0%
breast cancer system
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-04-08 (Crawled : 20:00) - globenewswire.com
IPSC | $2.95 -0.34% 29K
|
Professional, Scientific, and T...
|
| O: -1.59%
H: 8.87%
C: 7.8%
association cancer cell research preclinical for meeting technology therapeutics therapy platform
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
Published: 2024-04-08 (Crawled : 17:00) - globenewswire.com
INKT | $0.889 8.3K
|
|
| O: 1.28%
H: 0.0%
C: -16.46%
nk-215 liver cancer preclinical therapeutics
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
CORT | News | $22.48 -2.26% -2.31% 0
|
Health Technology
|
| O: 2.41%
H: 0.0%
C: -4.98%
cancer trial
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
CCCC | $6.265 -3.17% 110K
|
Health Technology
|
| O: -1.57%
H: 0.0%
C: 0.0%
cft1946 association approved cancer care research preclinical for meeting therapeutics
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
Published: 2024-04-08 (Crawled : 11:00) - globenewswire.com
KYMR | $35.21 -1.4% -1.51% 0
|
Health Technology
|
| O: 3.38%
H: 0.0%
C: -0.9%
association cancer research for meeting therapeutics
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
Published: 2024-04-08 (Crawled : 09:00) - biospace.com/
CALT | $18.5 700
|
Health Technology
|
| O: -1.06%
H: 3.5%
C: 0.51%
patent cancer treatment for application
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
Published: 2024-04-07 (Crawled : 00:00) - globenewswire.com
BDTX | $4.99 -1.38% 42K
|
Health Technology
|
| O: 5.22%
H: 3.44%
C: 2.1%
bdtx-1535 association presentation cancer research for meeting therapeutics
Gainers vs Losers
| 50% | 50% |
Top 10 Gainers
CSSE 4 | $0.299 96.32% 7M
|
Consumer Services
BRFH 4 | $1.99 80.91% 13M
|
Manufacturing
BOF | $1.915 63.68% 620K
|
AMST | $3.13 56.5% 500K
|
Technology Services
ACON | $0.3595 24.83% 3.5M
|
n/a
ILAG | $0.669 23.89% 13M
|
CDTX | News | $14.57 18.55% 330K
|
Health Technology
ULBI M | $10.12 15.92% 120K
|
Producer Manufacturing
LRHC | $1.79 11.88% 3K
|
n/a
AIXI | $1.34 8.94% 42K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.